All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-000020-32 | The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension | bad-data | |
| Reported results | 2004-000022-75 | Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk | 2005-11-09 | due-trials |
| Reported results | 2004-000033-11 | The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients with Moderate Hypertension | 2005-06-30 | due-trials |
| Reported results | 2004-000119-24 | Protocol CA165020: A Randomized, Two -Cohort Phase II Study of Two Doses of BMS-275183 Given On a Weekly Schedule in Patients with Pre-Treated Non- Small Cell Lung Cancer | 2006-03-29 | due-trials |
| Reported results | 2004-000202-49 | Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy Revised Pr... | 2007-12-12 | due-trials |
| Reported results | 2004-000822-58 | A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft | 2009-08-05 | due-trials |
| Completed, but no date, and reported results | 2004-000903-17 | A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Functioning of a Treatment with Aripiprazole in a Broad Range of Schizophrenic Patients | bad-data | |
| Reported results | 2004-000922-59 | A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination with Methotrexate in Controlling Disease Activity in Subjects with R... | 2009-07-03 | due-trials |
| Reported results | 2004-001128-19 | A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects ... | 2005-11-24 | due-trials |
| Reported results | 2004-001181-41 | A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia in General Psychiatric Practices | 2007-02-07 | due-trials |
| Reported results | 2004-002515-89 | A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate | 2008-04-09 | due-trials |
| Reported results | 2004-002516-28 | A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate | 2008-03-26 | due-trials |
| Reported results | 2004-002517-36 | A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Me... | 2007-12-07 | due-trials |
| Reported results | 2004-002601-69 | A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Imatin... | 2008-04-07 | due-trials |
| Reported results | 2004-002620-18 | A Multi-National Randomized, Double-Blind, Exploratory Study of Abatacept versus Placebo in Preventing the Development of Rheumatoid Arthritis in Adult Subjects with Undifferentiated Inflammatory Arth... | 2008-04-04 | due-trials |
| Reported results | 2004-002740-10 | A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, versio... | 2008-06-25 | due-trials |
| Reported results | 2004-002880-26 | A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV) Protocol: version 2.0, 2... | 2009-03-31 | due-trials |
| Reported results | 2004-002974-48 | Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT) Amendment 1 and Revised protocol Number:01 (Incorporates Amendment... | 2014-09-30 | due-trials |
| Reported results | 2004-003635-31 | Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT). Revised Protocol 05 incorporating Protocol Amendments 13 (dated 10-Feb-2011) | 2015-11-18 | due-trials |
| Reported results | 2004-004051-19 | A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Glucoco... | 2008-10-31 | due-trials |
| Reported results | 2004-004450-96 | A Randomized Multi-center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Dise... | 2008-03-31 | due-trials |
| Reported results | 2004-004604-20 | An Open-Label, Two-Stage, Fixed-Dose, Multicenter Phase II Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease | 2008-06-23 | due-trials |
| Reported results | 2004-005040-27 | An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03 | 2007-07-25 | due-trials |
| Reported results | 2004-005059-32 | A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Pat... | 2009-08-27 | due-trials |
| Reported results | 2004-005102-68 | A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs W... | 2009-08-11 | due-trials |
| Trial is outside EEC, and reported results | 2005-000443-28 | A Phase III, Multi-Center, Multi-National, Randomized, Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents with Active Polyarticular Juvenile Rheumatoid Arth... | bad-data | |
| Reported results | 2005-000472-40 | A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy with... | 2007-04-06 | due-trials |
| Reported results | 2005-000614-12 | Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome. | 2007-02-22 | due-trials |
| Reported results | 2005-000784-26 | A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Co... | 2009-10-13 | due-trials |
| Reported results | 2005-000865-21 | A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir in ... | 2008-01-31 | due-trials |
| Reported results | 2005-001169-32 | A Randomized Two-Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelera... | 2013-06-30 | due-trials |
| Completed, but no date, and reported results | 2005-001233-16 | Efficacy of Aripiprazole in Combination with Lithium or Valproate in the Long Term Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Lithium or Valproate Monotherapy R... | bad-data | |
| Reported results | 2005-001294-99 | A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase... | 2014-07-14 | due-trials |
| Reported results | 2005-001388-71 | A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Dee... | 2007-03-27 | due-trials |
| Reported results | 2005-001463-64 | A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Revised Protocol #01, version 2.0 incorporating Pro... | 2007-11-05 | due-trials |
| Reported results | 2005-001809-25 | A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment with Aripiprazole in Patients with Schizophrenia + Pharmacogenetics Bloo... | 2007-09-27 | due-trials |
| Reported results | 2005-001895-11 | A 96 Week Phase IIIB Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir ATV/RTV with Lopinavir/ritonavir LPV/RTV , Each in Combination with Fixed Dose Tenofovir-Emtricitabin... | 2008-10-28 | due-trials |
| Reported results | 2005-002051-41 | A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma Revised Protocol 01, incorporating Amendment 02... | 2007-07-24 | due-trials |
| Reported results | 2005-002126-64 | A Randomized Phase II Study to Determine Potential Predictive Markers of Response to MDX-010 BMS-734016 in Patients with Unresectable Stage III or IV Malignant Melanoma | 2008-02-03 | due-trials |
| Reported results | 2005-002678-31 | Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of Ipilimumab Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients with Unresectable Sta... | 2007-08-01 | due-trials |
| Reported results | 2005-002809-23 | Electrophysiological effects of Irbesartan in patients with paroxysmal AF Efectos electrofisiológicos del Irbesartán en sujetos con FA paroxística | 2007-06-28 | due-trials |
| Reported results | 2005-002848-25 | Protocol Title: A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate The Analgesic Efficacy And Safety of IV Paracetamol Versus Placebo in subjects with postoperat... | 2008-02-08 | due-trials |
| Reported results | 2005-002882-35 | Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005. Decision number of Paediatric Investigat... | 2019-05-22 | due-trials |
| Reported results | 2005-003265-16 | A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma Rev... | 2009-05-15 | due-trials |
| Reported results | 2005-003284-22 | Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection: The REALM Study Revised Protocol 1... | 2016-10-26 | due-trials |
| Reported results | 2005-003733-40 | A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma TCC of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcit... | 2008-07-30 | due-trials |
| Reported results | 2005-004338-42 | A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute Coronary Syndrome | 2008-05-27 | due-trials |
| Reported results | 2005-004575-37 | A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocortic... | 2011-08-02 | due-trials |
| Reported results | 2005-005022-31 | Effect of a High-Fat or a Light Meal Relative to Fasting Conditions on the Pharmacokinetics of Atazanavir when Administered with Ritonavir in Healthy Subjects | 2006-05-16 | due-trials |
| Reported results | 2005-005099-33 | A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients | 2007-01-29 | due-trials |
| Reported results | 2005-005119-76 | Phase IIIb Multicenter, Single Arm, Open-label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance with Atazanavir/ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infect... | 2009-05-04 | due-trials |
| Reported results | 2005-005153-22 | An open-label, randomized study of dasatinib vs. high-dose 800 mg imatinib in the treatment of subjects with chronic phase chronic myeloid leukemia who have had a suboptimal response after at leas... | 2010-01-20 | due-trials |
| Reported results | 2005-005238-11 | Belatacept Conversion Trial in Renal Transplantation | 2013-06-07 | due-trials |
| Trial is partly outside EEC, and reported results | 2005-005816-26 | Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. Revised Protocol... | 2017-09-04 | bad-data |
| Reported results | 2005-006082-14 | A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Da... | 2013-11-14 | due-trials |
| Reported results | 2005-006083-57 | A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols | 2014-03-18 | due-trials |
| Reported results | 2006-000006-23 | A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxaglipt... | 2008-12-09 | due-trials |
| Reported results | 2006-000421-62 | A Comparative Study of Chronic Hepatitis B Subjects Treated with Entecavir Plus Tenofovir Combination Therapy vs Entecavir Monotherapy in Adults who are Treatment-Naïve to Nucleosides and Nucleotides:... | 2011-03-11 | due-trials |
| Reported results | 2006-000422-31 | A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Subjects: The DEFINE Study Revised Protocol 02, incorpo... | 2012-06-04 | due-trials |
| Reported results | 2006-000453-22 | Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection | 2011-03-10 | due-trials |
| Reported results | 2006-001012-68 | A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients wi... | 2010-04-16 | due-trials |
| Completed, but no date, and reported results | 2006-001279-39 | A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or... | bad-data | |
| Reported results | 2006-001921-25 | A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer | 2009-11-02 | due-trials |
| Reported results | 2006-002045-36 | Phase II Study of Dasatinib BMS-354825 for Advanced Triple-negative Breast Cancer | 2008-09-09 | due-trials |
| Reported results | 2006-002147-91 | "Estudio BMS CV185030- Estudio fase III, controlado con Warfarina, aleatorizado, doble ciego y de brazos paralelos, para evaluar la seguridad y la eficacia de Apixaban en la prevención de accidente ce... | 2011-05-25 | due-trials |
| Reported results | 2006-002161-39 | A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee R... | 2008-05-28 | due-trials |
| Reported results | 2006-002178-23 | Phase II Study of Dasatinib BMS-354825 for Advanced Estrogen/Progesterone Receptor-Positive or Her2/neu-Positive Breast Cancer | 2009-05-06 | due-trials |
| Reported results | 2006-002205-31 | Phase II Study of Dasatinib BMS-354825 for Androgen-Deprived Progressive Prostate Cancer | 2010-10-18 | due-trials |
| Reported results | 2006-003047-24 | A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer Revised Protocol 02... | 2009-12-31 | due-trials |
| Reported results | 2006-003114-17 | A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, v... | 2012-08-08 | due-trials |
| Reported results | 2006-003163-31 | Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjects.... | 2007-12-15 | due-trials |
| Reported results | 2006-003371-13 | A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohns Disease (... | 2009-08-12 | due-trials |
| Reported results | 2006-003604-19 | A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Col... | 2009-11-19 | due-trials |
| Reported results | 2006-003674-96 | A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Follo... | 2011-05-18 | due-trials |
| Reported results | 2006-003768-67 | A Phase III Multicenter, Randomized, Double-Blind, placebo-controlled Study to Assess short-term changes in synovitis and structural damage outcomes in subjects with active Rheumatoid Arthritis and in... | 2010-05-25 | due-trials |
| Reported results | 2006-005351-14 | A Phase 3, Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery | 2009-09-05 | due-trials |
| Reported results | 2006-005712-27 | An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromoso... | 2015-12-22 | due-trials |
| Reported results | 2006-006896-19 | A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total K... | 2009-01-30 | due-trials |
| Reported results | 2007-000416-91 | A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or Locally Advanced Solid Malignancies.... | 2008-12-30 | due-trials |
| Reported results | 2007-000713-11 | An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers in S... | 2008-06-30 | due-trials |
| Reported results | 2007-000721-21 | Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer | 2011-11-30 | due-trials |
| Reported results | 2007-001217-42 | A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome | 2019-03-17 | due-trials |
| Reported results | 2007-001256-39 | A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol/Paraplatin (Paclitaxel/Carboplatin)... | 2013-07-31 | due-trials |
| Reported results | 2007-001269-14 | A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir versus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine Resistant Chronic Hepatitis B Virus Infect... | 2009-02-03 | due-trials |
| Exempt, with results Terminated | 2007-001432-31 | A Phase 1/2a, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 02, incorporating Protocol Amendmen... | not-yet-due | |
| Exempt, with results Terminated | 2007-001433-34 | A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 04, incorporating Protocol Amendment ... | 2009-12-10 | not-yet-due |
| Reported results | 2007-001557-26 | Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial +... | 2018-05-25 | due-trials |
| Reported results | 2007-001974-10 | Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC M... | 2018-11-26 | due-trials |
| Reported results | 2007-002125-68 | Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients | 2011-05-02 | due-trials |
| Reported results | 2007-002544-25 | A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in Subjects with Active Ulcerative Colitis | 2009-09-14 | due-trials |
| Reported results | 2007-003624-37 | Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Long T... | 2014-12-12 | due-trials |
| Reported results | 2007-003993-24 | A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma | 2009-10-12 | due-trials |
| Reported results | 2007-004138-17 | Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída. Phase 3 Ran... | 2010-03-15 | due-trials |
| Reported results | 2007-004241-15 | A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis. | 2011-01-19 | due-trials |
| Reported results | 2007-004953-27 | A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm and de... | 2012-08-24 | due-trials |
| Reported results | 2007-005097-31 | A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras wild type Subjects with Metastatic Colorectal Cancer. Revised Protocol 03... | 2012-12-21 | due-trials |
| Reported results | 2007-005209-23 | Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/or ... | 2011-05-30 | due-trials |
| Reported results | 2007-005434-37 | A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arthrit... | 2014-09-12 | due-trials |
| Reported results | 2007-005959-42 | A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patien... | 2012-10-05 | due-trials |
| Reported results | 2007-007867-25 | A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. Revised Protocol Number 02 incorporating Amendment(s) 04 and Ad... | 2013-03-12 | due-trials |
| Reported results | 2008-000087-16 | A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Letter 01 ... | 2013-12-05 | due-trials |
| Reported results | 2008-000170-20 | A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate ... | 2009-09-30 | due-trials |
| Reported results | 2008-000701-11 | A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer Revised Protocol 03 incorporating Admini... | 2015-07-31 | due-trials |
| Reported results | 2008-000976-26 | A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate The Efficacy and Safety of Saxagliptin in Comparison to Placebo as Add-on Treatment to Metformin XR in Sub... | 2009-02-27 | due-trials |
| Reported results | 2008-000977-39 | A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer | 2011-09-02 | due-trials |
| Reported results | 2008-001089-10 | A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Subjects with Typ... | 2010-11-08 | due-trials |
| Reported results | 2008-001523-57 | Estudio abierto y multicéntrico de evaluación de la respuesta temprana a abatacept con metotrexato de fondo mediante ecografía Power-Doppler en pacientes con artritis reumatoide activa y respuesta ins... | 2011-10-28 | due-trials |
| Reported results | 2008-001921-33 | A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in S... | 2011-06-21 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-002260-33 | A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib Revised Pr... | bad-data | |
| Reported results | 2008-003183-19 | A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin) plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer after Disease Progres... | 2012-12-30 | due-trials |
| Reported results | 2008-003314-97 | A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxe... | 2015-07-03 | due-trials |
| Reported results | 2008-003364-19 | A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Co... | 2010-05-06 | due-trials |
| Reported results | 2008-003533-24 | A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study) Pharmacogenetics ... | 2013-09-26 | due-trials |
| Reported results | 2008-004691-44 | A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients Revised Protocol Number 02, incorpor... | 2012-07-07 | due-trials |
| Reported results | 2008-005084-34 | A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or... | 2017-08-29 | due-trials |
| Reported results | 2008-005929-11 | A Multicenter, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Mild to Moderat... | 2010-06-07 | due-trials |
| Reported results | 2008-006561-89 | A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Canc... | 2011-10-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2008-007167-16 | A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have... | 2014-02-24 | bad-data |
| Reported results | 2008-007768-41 | A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with ... | 2013-08-28 | due-trials |
| Reported results | 2008-008298-77 | A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome | 2011-03-04 | due-trials |
| Reported results | 2008-008715-26 | A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinom... | 2018-01-26 | due-trials |
| Reported results | 2009-010067-16 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alz... | 2013-07-09 | due-trials |
| Reported results | 2009-010149-29 | A Phase 2a Study of BMS-790052 in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects with Chronic Hepatitis C Virus Genotype 1 Infection | 2011-01-24 | due-trials |
| Completed, but no date, and reported results | 2009-010221-39 | An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemic and Blood Pressure (BP) Control Ph... | bad-data | |
| Reported results | 2009-010224-25 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, PO, BID, in Combination with Metformin in Subjects... | 2010-02-24 | due-trials |
| Exempt, with results | 2009-010572-20 | A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects with Advanced and/or Metastatic Solid Tumors | 2010-08-04 | not-yet-due |
| Reported results | 2009-010576-21 | Randomized phase II of CCNU versus CCNU-dasatinib in patients with recurrent glioblastoma | 2011-05-24 | due-trials |
| Reported results | 2009-013652-69 | A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. | 2012-10-23 | due-trials |
| Reported results | 2009-013657-14 | Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects | 2010-06-22 | due-trials |
| Exempt, with results | 2009-013766-78 | A Phase I/II Trial of BMS-754807 in Combination with Trastuzumab (Herceptin®) in Subjects with Advanced or Metastatic Her-2-positive Breast Cancer Revised Protocol Number 01 (version 2.0, dated 01-J... | 2012-02-13 | not-yet-due |
| Reported results | 2009-015705-40 | A Study of the Safety and Efficacy of Entecavir plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure. | 2014-02-18 | due-trials |
| Reported results | 2009-016217-23 | Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prost... | 2015-09-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-016357-17 | A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive | 2018-04-03 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-016361-28 | A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with Ritonavir (RTV) Liquid with an Opti... | 2017-09-11 | bad-data |
| Reported results | 2009-016622-13 | An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Positi... | 2010-12-16 | due-trials |
| Reported results | 2009-017032-41 | An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and ... | 2014-02-18 | due-trials |
| Reported results | 2009-017396-19 | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subject... | 2017-08-22 | due-trials |
| Reported results | 2010-018295-24 | A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection Revised Protocol Number 03, inc... | 2012-08-29 | due-trials |
| Reported results | 2010-018674-20 | A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy... | 2014-12-18 | due-trials |
| Reported results | 2010-019378-34 | A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with Pe... | 2012-12-20 | due-trials |
| Reported results | 2010-019797-32 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately contr... | 2013-06-14 | due-trials |
| Reported results | 2010-019798-13 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Contr... | 2013-02-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-020347-12 | A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma Protocollo CA204004: Studio di fase 3, randomizzato, in a... | 2021-04-21 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-020360-38 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin (BMS-477118) as Monotherapy in Pediatric Patient... | 2016-04-22 | bad-data |
| Reported results | 2010-020387-38 | Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection w... | 2013-12-13 | due-trials |
| Reported results | 2010-022408-28 | A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection + ... | 2012-09-13 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-022445-20 | A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma. Ensayo de fase 3, aleatorizado y abierto, d... | 2021-09-04 | bad-data |
| Reported results | 2010-022506-41 | A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC) S... | 2015-03-02 | due-trials |
| Reported results | 2010-022568-11 | A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-65003... | 2014-09-24 | due-trials |
| Reported results | 2010-022841-93 | A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients with Treatment Resistant Major Depression Revised protocol 03(da... | 2013-01-28 | due-trials |
| Reported results | 2010-022947-39 | Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fibri... | 2012-06-13 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-023956-99 | A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrex... | 2015-06-10 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2010-024371-12 | A Multicenter, Double-Blind, 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression. Revised Protocol 01 Incorporating Protoc... | 2013-10-22 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-024537-23 | A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) Liquid with an Opti... | 2018-01-22 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-024568-16 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patien... | 2016-04-22 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-024597-19 | Multiple-Dose Study Apixaban in Pediatric Subjects with an Indwelling Central Venous Catheter | 2012-10-05 | bad-data |
| Reported results | 2011-000083-10 | An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib plus Smoothen Antagonist (BMS-833923) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philade... | 2016-01-25 | due-trials |
| Reported results | 2011-000437-36 | A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-labe... | 2017-05-12 | due-trials |
| Reported results | 2011-000732-29 | A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab versus Pemetrexed in Subjects with Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After F... | 2013-02-25 | due-trials |
| Reported results | 2011-000778-71 | A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depressi... | 2013-07-23 | due-trials |
| Reported results | 2011-000836-27 | An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C. Studio di ri-trattamento in aperto con Peg... | 2015-01-12 | due-trials |
| Reported results | 2011-000850-48 | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Sma... | 2017-08-04 | due-trials |
| Reported results | 2011-000853-22 | A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab versus best supportive care following first-line chemotherapy in subjects with unresectable locally ad... | 2015-04-02 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-001123-20 | A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukem... | bad-data | |
| Reported results | 2011-002024-40 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults with Active, Moderate to Severe Rheumatoid ... | 2013-02-13 | due-trials |
| Reported results | 2011-002695-16 | A Phase 2, Randomized Study of Bortezomib/dexamethasone With or Without Elotuzumab in Subjects with Relapsed/Refractory Multiple Myeloma. Studio di fase 2 randomizzato su bortezomib/desametasone co... | 2017-04-21 | due-trials |
| Reported results | 2011-002793-23 | A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotypes 1 and 4 Studio di Fase 3 per la valutazi... | 2014-01-23 | due-trials |
| Reported results | 2011-002957-67 | A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther... | 2021-04-26 | due-trials |
| Reported results | 2011-002981-19 | A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Crohn's Diseas... | 2014-12-29 | due-trials |
| Reported results | 2011-003067-30 | A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) a... | 2014-09-10 | due-trials |
| Reported results | 2011-003128-11 | Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutation Pharmacogenetics Blood Amendment 1; Revised Protocol 02 incorporating amendment 05 | 2014-07-23 | due-trials |
| Trial is outside EEC, and reported results | 2011-003300-21 | A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety of Atazanavir (ATV) Capsule Boosted with Ritonavir (RTV) with an Optimized NRTI Background Therapy, in HIV... | bad-data | |
| Reported results | 2011-003329-89 | A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-lab... | 2014-08-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-004016-29 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS- 945429 Subcutaneous Injection in Adults with Active Psoriatic Art... | 2015-06-18 | bad-data |
| Reported results | 2011-004029-28 | A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg vs at 10 mg/kg in Subjects with Previously Treated or Untreated Unresectable or Metastatic Melanoma. Studio di fase I... | 2017-08-17 | due-trials |
| Reported results | 2011-004237-14 | A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C Studio di fas... | 2014-03-20 | due-trials |
| Reported results | 2011-004695-11 | A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepat... | 2015-05-15 | due-trials |
| Reported results | 2011-004763-72 | A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subject... | 2013-12-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-004792-36 | An Open-Label Randomized Phase III Trial of 936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) Pharmacogenetics Blood Sa... | 2021-08-16 | bad-data |
| Reported results | 2011-004885-14 | A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combinatio... | 2014-09-24 | due-trials |
| Reported results | 2011-005121-49 | Phase 2a Single-Arm Safety Study of Elotuzumab in Combination with Thalidomide and Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma Estudio de Fase 2a, de un solo grupo, d... | 2016-03-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-005132-26 | A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Studio... | 2021-07-19 | bad-data |
| Trial is outside EEC, and reported results | 2011-005225-40 | A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years with Type 2 Diabetes Mellitus | bad-data | |
| Trial is partly outside EEC, and reported results | 2011-005257-31 | A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects with a Stable Renal Transplant Revised prot... | bad-data | |
| Reported results | 2011-005287-21 | A Long-Term Follow-up Study of Subjects Who Participated in A Clinical Trial in Which BMS-650032 and/or BMS-790052 Was Administered for the Treatment of Chronic Hepatitis C + Administrative Letter ... | 2018-03-16 | due-trials |
| Reported results | 2011-005293-31 | A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C Revised Protocol 01... | 2014-11-20 | due-trials |
| Reported results | 2011-005409-65 | A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis... | 2014-10-13 | due-trials |
| Reported results | 2011-005422-21 | A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterfero... | 2013-12-09 | due-trials |
| Reported results | 2011-005446-35 | A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects ... | 2014-09-29 | due-trials |
| Reported results | 2011-006180-21 | A PHASE IV, OPEN-LABEL, MULTICENTER STUDY OF DASATINIB IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS WITH CHRONIC LOW-GRADE NONHEMATOLOGIC TOXICITY TO IMATINIB | 2015-10-01 | due-trials |
| Reported results | 2011-006181-41 | An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy with ... | 2022-04-12 | due-trials |
| Reported results Terminated | 2011-006187-47 | A 48-Week, Randomized, Open-Label Phase 3b Study Comparing the Antiviral Efficacy and Safety of ATV/RTV Plus 3TC with ATV/RTV plus TDF/FTC in HIV-1-Infected, Treatment-Naive Subjects, Followed by a 48... | 2012-12-05 | due-trials |
| Reported results | 2011-006323-37 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combination ... | 2015-01-12 | due-trials |
| Reported results | 2011-006324-20 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Me... | 2015-02-19 | due-trials |
| Reported results | 2012-000070-28 | A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/R... | 2013-11-21 | due-trials |
| Reported results | 2012-000509-54 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects with Inadequately Control... | 2012-11-12 | due-trials |
| Reported results | 2012-000679-18 | A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy with Saxagliptin and Dapagliflozin added to Metformin co... | 2014-01-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-000714-11 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids... | 2018-05-30 | bad-data |
| Reported results | 2012-001314-42 | Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression | 2019-10-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-001421-27 | Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE | 2021-10-08 | bad-data |
| Exempt | 2012-001514-42 | A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab or Nivolumab in Combination with Other Agents in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis Studi... | not-yet-due | |
| Trial is outside EEC, and reported results | 2012-001581-15 | Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2012-001828-35 | A Randomized Open-Label Phase 3 Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy Pharmacogenetics Blood... | 2020-12-29 | bad-data |
| Trial is outside EEC, and reported results | 2012-001840-23 | An exploratory study of the biologic effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced melanoma (Unresectable or metastat... | bad-data | |
| Trial is partly outside EEC, and reported results | 2012-002249-39 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma Revised Protocol 00b - UK only - ... | 2016-07-07 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2012-002472-14 | An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC) | 2021-12-20 | bad-data |
| Reported results | 2012-002798-80 | A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis | 2020-06-30 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-003195-39 | A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile ... | 2023-02-01 | bad-data |
| Reported results | 2012-003280-22 | Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment naïv... | 2015-08-27 | due-trials |
| Reported results | 2012-003291-38 | A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment versus Chemotherapy for Subjects with Advanced Melanoma who Progressed after Initially Achieving Disease Control with Ipi... | 2014-07-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-003463-22 | A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Rela... | 2015-01-22 | bad-data |
| Reported results | 2012-003508-11 | A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon alfa-2a, Each in Combination with Ribavirin, in the Treatment of Naiv... | 2014-09-18 | due-trials |
| Reported results | 2012-003718-16 | A Phase 3, Randomized, Double-Blind Study of BMS-936558 (Nivolumab) vs Dacarbazine in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma Pharmacogenetics Blood Sample Amendment 0... | 2021-05-14 | due-trials |
| Reported results | 2012-003965-16 | A Single-Arm Phase 2 Study of BMS-936558 in Subjects with Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens | 2021-04-22 | due-trials |
| Reported results | 2012-004124-38 | Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 with Atazanavir +/- Ritonavir (Open-Labe... | 2014-11-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-004502-93 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer | 2022-05-27 | bad-data |
| Reported results | 2012-004531-23 | A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Su... | 2016-06-01 | due-trials |
| Reported results | 2012-005093-54 | A Double-Blind, Placebo-Controlled, Randomized, Twostage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects with Type 2 Diabetes Mellitus and Diabetic Ki... | 2015-06-12 | due-trials |
| Other | 2012-005371-13 | A Phase 3, Randomized, Double- Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated, Unresectable or Metastati... | not-yet-due | |
| Reported results | 2013-000055-41 | Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) | 2016-02-01 | due-trials |
| Reported results | 2013-002018-11 | Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination with Ipilimumab vs Ipilimumab alone in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma | 2021-02-26 | due-trials |
| Reported results | 2013-002090-21 | 2013-002090-21 | 2019-02-05 | due-trials |
| Reported results | 2013-002458-66 | A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis | 2014-11-26 | due-trials |
| Reported results | 2013-002468-20 | A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C | 2014-11-18 | due-trials |
| Exempt | 2013-002844-10 | A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors | not-yet-due | |
| Reported results | 2013-003621-28 | A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) o... | 2020-10-08 | due-trials |
| Reported results | 2013-003622-86 | An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) | 2021-09-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-003645-42 | A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) | 2020-12-28 | bad-data |
| Ongoing | 2013-003738-34 | A Randomized Phase 2b, Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) Revised Protocol 01, incorporati... | not-yet-due | |
| Reported results | 2013-003780-65 | A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have Exp... | 2015-06-17 | due-trials |
| Ongoing | 2013-003939-30 | A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer Revised Protocol 01 incorporating Protocol amendment 01 | not-yet-due | |
| Reported results | 2013-005487-26 | A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 I... | 2017-08-21 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-000328-47 | A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy ... | 2021-07-07 | bad-data |
| Reported results | 2014-001231-36 | A phase IV trial to assess the effectiveness of Apixaban compared with usual care anticoagulation in subjects with non-valvular Atrial Fibrillation undergoing cardioversion | 2017-02-08 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-001285-10 | An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Le... | 2021-08-27 | bad-data |
| Reported results | 2014-001286-28 | A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS- 936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treat... | 2019-01-18 | due-trials |
| Reported results | 2014-001429-33 | Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) | 2018-01-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-001509-42 | Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects | 2022-12-27 | bad-data |
| Ongoing | 2014-001750-42 | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma | not-yet-due | |
| Reported results | 2014-002004-24 | An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation a... | 2018-12-03 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-002111-41 | A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Re... | 2017-02-21 | bad-data |
| Reported results | 2014-002184-14 | A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of care in the Treatment o... | 2017-10-26 | due-trials |
| Exempt, with results | 2014-002241-22 | A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkin... | 2019-05-24 | not-yet-due |
| Trial is partly outside EEC | 2014-002351-26 | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for ... | bad-data | |
| Exempt, with results | 2014-002372-89 | A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung Cancer | 2022-12-21 | not-yet-due |
| Exempt, with results | 2014-002485-70 | A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors | 2020-05-07 | not-yet-due |
| Reported results | 2014-002604-25 | Randomized, Multicenter, Double- Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subject... | 2018-05-03 | due-trials |
| Trial is partly outside EEC | 2014-002605-38 | A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Mo... | bad-data | |
| Trial is partly outside EEC | 2014-002606-20 | A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT | bad-data | |
| Reported results | 2014-002987-34 | A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomat... | 2016-12-15 | due-trials |
| Reported results | 2014-003282-19 | An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma. | 2021-10-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003625-17 | A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent | 2021-11-12 | bad-data |
| Other | 2014-003626-40 | A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma | not-yet-due | |
| Ongoing | 2014-003630-23 | An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-N... | not-yet-due | |
| Trial is outside EEC | 2014-003963-39 | An In Vitro Comparison of Apixaban Activity in Adult and Pediatric Plasma | bad-data | |
| Trial is outside EEC, and reported results | 2014-003964-18 | Evaluation of the Pharmacokinetics of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin in Children and Adolescents Aged 10 to 17 Years with Type 2 Diabetes Mellitus Following Oral Administration of S... | bad-data | |
| Reported results | 2014-004278-40 | Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib | 2022-05-13 | due-trials |
| Trial is outside EEC, and reported results | 2014-005134-64 | Phase I/II Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, ATAZANAVIR, ATV, REYATAZ™) in Combination Regimens in Antiretroviral Therapy (ART)-Naïve and Experien... | bad-data | |
| Reported results | 2014-005310-28 | Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 weeks in Treatment-Naïve and Treatment-Experienced Patients with Genotype 3 Chronic Hepatitis C Infection with Comp... | 2015-12-18 | due-trials |
| Exempt, with results | 2015-000230-29 | Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors | 2022-10-24 | not-yet-due |
| Exempt, with results | 2015-000324-29 | A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced... | 2021-03-17 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2015-001097-18 | An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy | 2022-08-22 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-001274-17 | Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV... | 2020-02-20 | bad-data |
| Reported results | 2015-001275-50 | A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remi... | 2020-03-19 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-002441-61 | A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lun... | 2021-11-17 | bad-data |
| Exempt, with results | 2015-002505-11 | A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Anti... | 2019-12-16 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2015-002740-13 | A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma | 2024-02-07 | bad-data |
| Reported results | 2015-002887-17 | Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects with Moderate to... | 2018-05-03 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-003286-28 | A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression | 2022-02-07 | bad-data |
| Listed as ongoing, but also has a completion date | 2015-003339-36 | A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs | 2020-10-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003739-37 | A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methy... | 2022-03-04 | bad-data |
| Reported results Terminated | 2015-003959-22 | A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS-986141 For the Prevention of Recurrent Brain Infarction in Subjects receiving acetyls... | 2017-02-21 | due-trials |
| Reported results | 2015-004633-27 | A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4... | 2022-01-18 | due-trials |
| Ongoing | 2015-004722-34 | A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA met... | not-yet-due | |
| Exempt, with results | 2015-004816-39 | A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors Estudio fase 1/2a de BMS-986178 administrado en monoterapia y en combina... | 2020-11-02 | not-yet-due |
| Exempt, with results | 2015-004914-79 | A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors Estudio fase 1/2a de BMS-986205 administrado en ... | 2021-10-15 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2015-004920-67 | Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Unt... | 2021-05-28 | bad-data |
| Trial is outside EEC, and reported results | 2015-005450-36 | A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndro... | bad-data | |
| Ongoing | 2015-005556-10 | A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer | not-yet-due | |
| Reported results | 2015-005699-21 | An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma | 2022-03-09 | due-trials |
| Ongoing | 2016-000037-51 | Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab | not-yet-due | |
| Reported results | 2016-000101-37 | A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary Sjö... | 2017-07-24 | due-trials |
| Reported results | 2016-000461-23 | An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies | 2021-06-24 | due-trials |
| Exempt, with results | 2016-000603-91 | A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with N ivolumab (BMS-936558) in Subjects with Advanced Solid Tumors Studio di fase 1/2a di BMS-986179 somministrato in monoter... | 2021-10-12 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2016-000725-39 | An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in ... | 2022-09-22 | bad-data |
| Reported results | 2016-000894-19 | A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL) | 2020-11-24 | due-trials |
| Trial is outside EEC, and reported results | 2016-000940-32 | A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents with Active Juve... | bad-data | |
| Other | 2016-001018-76 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastr... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-001247-39 | A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart Dis... | 2021-10-18 | bad-data |
| Exempt, with results | 2016-001359-36 | A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors Ensayo fase 1/2 de la combinac... | not-yet-due | |
| Other | 2016-001514-20 | A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or M... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-001645-64 | A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma... | 2022-03-11 | bad-data |
| Reported results | 2016-001654-18 | A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy Étude randomisée, en doubl... | 2020-04-28 | due-trials |
| Reported results | 2016-001685-29 | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospit... | 2019-11-12 | due-trials |
| Exempt | 2016-001692-67 | A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer Ensayo fase 1/2 aleatorizado de BMS-986012 en c... | not-yet-due | |
| Reported results | 2016-001835-11 | A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (Master Protocol Revised version 02 dated 27-Jul-2016 + Sub-... | 2020-01-29 | due-trials |
| Listed as ongoing, but also has a completion date | 2016-001859-43 | A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma | 2023-05-30 | bad-data |
| Other | 2016-001928-54 | A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer | not-yet-due | |
| Reported results | 2016-001941-26 | Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects with Previously Untreated Unresectable or Metastatic Melanoma Estudio fase IIIb, aleatori... | 2019-10-25 | due-trials |
| Reported results Terminated | 2016-001948-19 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sj¿grens Syndrome Studio di Fase 3 Randomizz... | 2018-12-03 | due-trials |
| Reported results | 2016-002269-77 | A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adu... | 2022-08-02 | due-trials |
| Trial is partly outside EEC | 2016-002347-41 | Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin ly... | bad-data | |
| Reported results | 2016-002481-31 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | 2017-11-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002554-21 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy | 2020-02-07 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-002621-10 | A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer Studio di sicurezza di fase IIIb/IV sulla somministrazione di niv... | 2022-05-13 | bad-data |
| Reported results | 2016-002807-24 | A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer - Master Protocol Amendment 06 dated 13-Aug-2021 - Sub-protocol A ... | 2022-05-06 | due-trials |
| Trial is partly outside EEC | 2016-002898-35 | A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (T... | 2023-08-02 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-003082-26 | A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma Master Protocol Amendment 07, dated 11-Jan-2022 SubProtocol A... | 2021-11-23 | bad-data |
| Ongoing | 2016-003536-21 | Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC Studio di Fase III in ape... | not-yet-due | |
| Reported results | 2016-003586-26 | A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired S... | 2019-05-10 | due-trials |
| Other | 2016-003616-13 | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2016-003729-41 | A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma... | 2021-02-02 | bad-data |
| Ongoing, reported early | 2016-003731-37 | An Open-label, single-arm Phase II Safety Study of Nivolumab in Subjects with Advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior systemi... | not-yet-due | |
| Ongoing | 2016-003881-14 | A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab or with Standard of Care Chemotherapy versus Standard of Care Chemotherapy in Participants with Previously Untreated Unres... | not-yet-due | |
| Exempt, with results | 2016-004275-40 | A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) In Combination with Low Dose Cytarabine in Subjects with Newly Diagnosed Acute Myeloid Leukemia | 2019-06-04 | not-yet-due |
| Trial is partly outside EEC, and reported results | 2016-004441-82 | Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies | 2022-01-17 | bad-data |
| Listed as ongoing, but also has a completion date | 2016-004502-34 | A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial ... | 2024-02-01 | bad-data |
| Exempt, with results Terminated | 2017-000238-73 | A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or... | 2021-12-20 | not-yet-due |
| Exempt, with results | 2017-000367-33 | Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors | 2020-07-02 | not-yet-due |
| Exempt | 2017-000597-11 | Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors. | not-yet-due | |
| Other | 2017-000759-20 | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advan... | not-yet-due | |
| Other | 2017-001195-35 | A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-001203-79 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus | 2021-10-28 | bad-data |
| Ongoing | 2017-001626-17 | A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer | not-yet-due | |
| Exempt | 2017-001725-40 | A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors. | 2023-06-14 | not-yet-due |
| Exempt | 2017-001830-24 | A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers Estudio de nivolumab en combinación con trametin... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2017-001976-48 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease | 2023-10-23 | bad-data |
| Trial is partly outside EEC, and reported results | 2017-002499-14 | A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated | 2020-07-10 | bad-data |
| Reported results Terminated | 2017-002672-38 | Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cance... | 2022-10-17 | due-trials |
| Reported results | 2017-002676-87 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligibl... | 2019-10-14 | due-trials |
| Other | 2017-002755-29 | A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Abl... | not-yet-due | |
| Reported results | 2017-003059-46 | A Randomized, Global, Open-label Study of Nivolumab in Combination with BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck | 2018-09-04 | due-trials |
| Trial is partly outside EEC, and reported results | 2017-003338-94 | Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Daclatasvir (DCV) in Combination with Sofosbuvir (SOF) in Children from 3 to less than 18 Years of Age with GT-1 t... | 2020-12-17 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-003581-27 | A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cance... | 2022-08-22 | bad-data |
| Trial is partly outside EEC | 2017-003583-12 | A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma | bad-data | |
| Reported results Terminated | 2017-003662-27 | An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer Ensayo de fase 2/3 abierto... | 2022-08-19 | due-trials |
| Other | 2017-004692-31 | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2017-004896-30 | A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in C... | 2018-10-02 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-005029-19 | A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarctio... | 2022-03-31 | bad-data |
| Ongoing | 2018-000040-26 | A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) ... | not-yet-due | |
| Exempt | 2018-000058-22 | A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with... | not-yet-due | |
| Other | 2018-000237-12 | A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Be... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-000339-28 | A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without chemotherapy in Patients with Advanced Pancreatic Cancer | 2023-06-01 | bad-data |
| Exempt | 2018-000340-26 | A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers | not-yet-due | |
| Exempt | 2018-000416-21 | A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-000462-11 | An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC) | 2023-04-24 | bad-data |
| Reported results | 2018-000970-31 | A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8 Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired Systolic Function Given a ... | 2020-01-09 | due-trials |
| Exempt | 2018-001030-17 | Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-001069-18 | A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG- 3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment i... | 2024-01-25 | bad-data |
| Reported results Terminated | 2018-001070-20 | A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination with Various Standard-of-Care Therapeutic Regimens, in Participants with Recurrent, Locally Advanced, ... | 2019-05-16 | due-trials |
| Trial is partly outside EEC | 2018-001423-40 | A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma | 2024-03-19 | bad-data |
| Exempt | 2018-001585-42 | Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-001925-24 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjec... | 2020-11-30 | bad-data |
| Trial is partly outside EEC, and reported results | 2018-001926-25 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis | 2020-09-02 | bad-data |
| Exempt, with results | 2018-002108-15 | Phase 1/2 Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors | 2020-12-29 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2018-002676-40 | A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisp... | 2023-06-09 | bad-data |
| Other | 2018-003151-38 | A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase... | not-yet-due | |
| Exempt | 2018-003200-39 | A Phase 1/2 Study to Compare Bempegaldesleukin Combined with Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI alone in Participants with Previously Untreated Advanced or Metastatic... | not-yet-due | |
| Other | 2018-003471-35 | A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-003719-23 | A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention with Adjuvant Nivolumab in Non- Small Cell Lung Cancer Participants with ctDNA detected Minimal Residual Disease after Surgical Res... | 2020-04-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-004142-42 | A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis | 2021-09-17 | bad-data |
| Exempt | 2018-004283-65 | A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Chemotherapy... | 2020-12-07 | not-yet-due |
| Reported results | 2018-004293-10 | A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA) | 2021-01-27 | due-trials |
| Ongoing | 2018-004362-34 | Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004694-27 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis | 2023-04-04 | bad-data |
| Ongoing | 2018-004695-35 | A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or ... | not-yet-due | |
| Exempt | 2019-000132-25 | A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Mel... | 2023-07-26 | not-yet-due |
| Other | 2019-000252-34 | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma | not-yet-due | |
| Other | 2019-000262-38 | A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab ... | not-yet-due | |
| Other | 2019-000612-29 | An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis | not-yet-due | |
| Other | 2019-001222-98 | A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followe... | not-yet-due | |
| Trial is partly outside EEC | 2019-001230-34 | A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clin... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2019-001334-34 | Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer >= 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole | 2021-07-27 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-002030-36 | A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men With Advanced Castration-resitant Prostate Cancer Studio di Fase 3, randomizzato, in doppio ci... | 2023-07-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-002205-22 | "A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögren’... | 2022-12-05 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-002469-37 | A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-... | 2023-12-27 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-002567-96 | A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is ... | 2023-10-31 | bad-data |
| Completed, report not yet due | 2019-002790-58 | A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) ... | 2023-12-12 | not-yet-due |
| Other | 2019-003055-11 | A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-003932-22 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Ste... | 2024-02-09 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-003992-21 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis | 2023-09-22 | bad-data |
| Other | 2019-004021-25 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants with Active Systemic Lupus Erythematosus. | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-004186-40 | A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure | 2021-07-19 | bad-data |
| Exempt, with results | 2019-004380-40 | A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab | not-yet-due | |
| Completed, report not yet due | 2019-004878-26 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis. | 2023-11-29 | not-yet-due |
| Other | 2019-004879-39 | A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BMS-986165 in Adolescent Subjects with Moderate to Severe Plaque Psori... | not-yet-due | |
| Other | 2020-000071-21 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Participants with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) | not-yet-due | |
| Other | 2020-000350-96 | A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2020-000854-85 | Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) | 2022-06-22 | bad-data |
| Ongoing | 2020-001863-10 | A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | not-yet-due | |
| Exempt | 2020-002071-35 | A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination with Either Ruxolitinib or Fedratinib in Participants with DIPSS-Intermediate or High Risk Myelofibrosis | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-002885-15 | An Open-label, Randomized Crossover Study to Obtain a Preliminary Estimate of the Bioavailability of Atazanavir and Cobicistat When Administered in an Age-appropriate Fixed‑dose Combination Formulatio... | bad-data | |
| Ongoing | 2020-003655-15 | A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinom... | not-yet-due | |
| Ongoing | 2020-004026-31 | A Phase 2 Randomized Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recur... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2020-004461-40 | An Open-label, Multi-center Extension Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants with Moderate to Severe Crohn's Disease or Moderate to Severe Ulcerative Colitis... | 2023-08-31 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-004767-77 | A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis | 2022-08-24 | bad-data |
| Other | 2020-005097-10 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-m... | not-yet-due | |
| Other | 2020-005099-36 | POETYK PsA-2 (055) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Participants with Active Psoriatic Arthritis (PsA) ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-000039-29 | A Phase 2 Randomized Double-blind Study of BMS-986207 in Combination with Nivolumab and Ipilimumab as First-line Treatment for Participants with Stage IV Non-Small Cell Lung Cancer Estudio en fase ... | 2022-12-27 | bad-data |
| Exempt | 2021-000493-29 | A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical H... | not-yet-due | |
| Exempt | 2021-001188-26 | A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors Estudio fase 1/2 de BMS-986340 en monoterapia y en combinación con nivolu... | not-yet-due | |
| Trial is partly outside EEC | 2021-001641-13 | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma | bad-data | |
| Listed as ongoing, but also has a completion date | 2021-003208-42 | A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Administered Subcutaneously (Nivo SC) Versus Intravenous Administration of Nivolumab in Participants with Stage II... | 2024-02-08 | bad-data |
| Exempt | 2021-003606-53 | A Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellula... | not-yet-due | |
| Ongoing | 2021-003990-74 | A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer | not-yet-due | |
| Exempt | 2021-004284-27 | A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors Primer ensayo en seres humanos, fase 1/2 de BMS-986288 en monoterapia y en combin... | not-yet-due | |
| Other | 2021-004285-35 | A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of M... | not-yet-due | |
| Ongoing | 2021-004807-42 | A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, versus Investigator's Choice Chemotherapy in Women with Platin... | not-yet-due | |
| Ongoing | 2022-000131-23 | A Phase 2 Open-label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NS... | not-yet-due | |
| Completed, report not yet due Terminated | 2022-000294-67 | A Phase II Study of Adjuvant Nivolumab Switch from Intravenous (IV) to Subcutaneous (SC) Use in Participants with Resected Stage III or Stage IV Melanoma or High Risk Invasive Urothelial Carcinoma Ori... | 2023-03-20 | not-yet-due |
| Ongoing | 2022-000797-26 | A PHASE 3B/4, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DEUCRAVACITINIB IN PARTICIPANTS WITH MODERATE-TO-SEVERE SCALP PSORIASIS (PSORIATYK S... | not-yet-due |